These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 23857972)
1. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. Crown JP; Diéras V; Staroslawska E; Yardley DA; Bachelot T; Davidson N; Wildiers H; Fasching PA; Capitain O; Ramos M; Greil R; Cognetti F; Fountzilas G; Blasinska-Morawiec M; Liedtke C; Kreienberg R; Miller WH; Tassell V; Huang X; Paolini J; Kern KA; Romieu G J Clin Oncol; 2013 Aug; 31(23):2870-8. PubMed ID: 23857972 [TBL] [Abstract][Full Text] [Related]
2. Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy. Clemons M; Joy AA; Abdulnabi R; Kotliar M; Lynch J; Jordaan JP; Iscoe N; Gelmon K Breast Cancer Res Treat; 2010 Nov; 124(1):177-86. PubMed ID: 20814815 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644 [TBL] [Abstract][Full Text] [Related]
4. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317 [TBL] [Abstract][Full Text] [Related]
5. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571 [TBL] [Abstract][Full Text] [Related]
6. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational? Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266 [TBL] [Abstract][Full Text] [Related]
7. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. Jassem J; Fein L; Karwal M; Campone M; Peck R; Poulart V; Vahdat L Breast; 2012 Feb; 21(1):89-94. PubMed ID: 21937232 [TBL] [Abstract][Full Text] [Related]
8. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Thomas ES; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Pivot XB; Klimovsky JV; de Mendoza FH; Xu B; Campone M; Lerzo GL; Peck RA; Mukhopadhyay P; Vahdat LT; Roché HH J Clin Oncol; 2007 Nov; 25(33):5210-7. PubMed ID: 17968020 [TBL] [Abstract][Full Text] [Related]
9. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927 [TBL] [Abstract][Full Text] [Related]
10. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Pallis AG; Boukovinas I; Ardavanis A; Varthalitis I; Malamos N; Georgoulias V; Mavroudis D Ann Oncol; 2012 May; 23(5):1164-1169. PubMed ID: 21937705 [TBL] [Abstract][Full Text] [Related]
11. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of Pseudomonas aeruginosa-Mannose-Sensitive hemagglutinin in combination with capecitabine for Her-2-negative metastatic breast cancer pretreated with anthracycline and taxane. Lv F; Cao J; Liu Z; Wang Z; Zhang J; Zhang S; Wang L; Zhao X; Shao Z; Wang B; Hu X PLoS One; 2015; 10(3):e0118607. PubMed ID: 25768439 [TBL] [Abstract][Full Text] [Related]
13. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials. Fornier M Clin Breast Cancer; 2010 Oct; 10(5):352-8. PubMed ID: 20920979 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K Tumori; 2015; 101(4):418-23. PubMed ID: 25953439 [TBL] [Abstract][Full Text] [Related]
15. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. O'Shaughnessy J; Miles D; Vukelja S; Moiseyenko V; Ayoub JP; Cervantes G; Fumoleau P; Jones S; Lui WY; Mauriac L; Twelves C; Van Hazel G; Verma S; Leonard R J Clin Oncol; 2002 Jun; 20(12):2812-23. PubMed ID: 12065558 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. Vahdat LT; Vrdoljak E; Gómez H; Li RK; Bosserman L; Sparano JA; Baselga J; Mukhopadhyay P; Valero V J Geriatr Oncol; 2013 Oct; 4(4):346-52. PubMed ID: 24472478 [TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153 [TBL] [Abstract][Full Text] [Related]
18. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Sparano JA; Vrdoljak E; Rixe O; Xu B; Manikhas A; Medina C; Da Costa SC; Ro J; Rubio G; Rondinon M; Perez Manga G; Peck R; Poulart V; Conte P J Clin Oncol; 2010 Jul; 28(20):3256-63. PubMed ID: 20530276 [TBL] [Abstract][Full Text] [Related]
19. A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines. Campone M; Dobrovolskaya N; Tjulandin S; Chen SC; Fourie S; Mefti F; Konstantinova M; Lefresne F; Meheust N; Jassem J Breast J; 2013; 19(3):240-9. PubMed ID: 23528159 [TBL] [Abstract][Full Text] [Related]
20. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Lück HJ; Du Bois A; Loibl S; Schrader I; Huober J; Heilmann V; Beckmann M; Stähler A; Jackisch C; Hubalek M; Richter B; Stickeler E; Eidtmann H; Thomssen C; Untch M; Wollschläger K; Schuster T; von Minckwitz G Breast Cancer Res Treat; 2013 Jun; 139(3):779-87. PubMed ID: 23771714 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]